ORIC Pharmaceuticals Statistics
Total Valuation
ORIC has a market cap or net worth of $1.17 billion. The enterprise value is $913.55 million.
| Market Cap | 1.17B |
| Enterprise Value | 913.55M |
Important Dates
The next estimated earnings date is Thursday, November 12, 2026, after market close.
| Earnings Date | Nov 12, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ORIC has 103.65 million shares outstanding. The number of shares has increased by 43.06% in one year.
| Current Share Class | 103.65M |
| Shares Outstanding | 103.65M |
| Shares Change (YoY) | +43.06% |
| Shares Change (QoQ) | +2.41% |
| Owned by Insiders (%) | 1.04% |
| Owned by Institutions (%) | 106.77% |
| Float | 88.69M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 3.21 |
| P/TBV Ratio | 3.14 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.19, with a Debt / Equity ratio of 0.02.
| Current Ratio | 13.19 |
| Quick Ratio | 12.76 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -39.80% and return on invested capital (ROIC) is -27.13%.
| Return on Equity (ROE) | -39.80% |
| Return on Assets (ROA) | -25.97% |
| Return on Invested Capital (ROIC) | -27.13% |
| Return on Capital Employed (ROCE) | -40.67% |
| Weighted Average Cost of Capital (WACC) | 9.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.26M |
| Employee Count | 111 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -17.32% in the last 52 weeks. The beta is 0.98, so ORIC's price volatility has been similar to the market average.
| Beta (5Y) | 0.98 |
| 52-Week Price Change | -17.32% |
| 50-Day Moving Average | 13.02 |
| 200-Day Moving Average | 10.96 |
| Relative Strength Index (RSI) | 33.16 |
| Average Volume (20 Days) | 1,580,349 |
Short Selling Information
The latest short interest is 16.32 million, so 15.74% of the outstanding shares have been sold short.
| Short Interest | 16.32M |
| Short Previous Month | 17.53M |
| Short % of Shares Out | 15.74% |
| Short % of Float | 18.40% |
| Short Ratio (days to cover) | 11.16 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -156.14M |
| Pretax Income | -140.35M |
| Net Income | -140.35M |
| EBITDA | -155.00M |
| EBIT | -156.14M |
| Earnings Per Share (EPS) | -$1.35 |
Balance Sheet
The company has $264.76 million in cash and $6.00 million in debt, with a net cash position of $258.76 million or $2.50 per share.
| Cash & Cash Equivalents | 264.76M |
| Total Debt | 6.00M |
| Net Cash | 258.76M |
| Net Cash Per Share | $2.50 |
| Equity (Book Value) | 381.26M |
| Book Value Per Share | 3.68 |
| Working Capital | 252.94M |
Cash Flow
In the last 12 months, operating cash flow was -$111.64 million and capital expenditures -$620,000, giving a free cash flow of -$112.26 million.
| Operating Cash Flow | -111.64M |
| Capital Expenditures | -620,000 |
| Depreciation & Amortization | 1.14M |
| Net Borrowing | n/a |
| Free Cash Flow | -112.26M |
| FCF Per Share | -$1.08 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ORIC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -43.06% |
| Shareholder Yield | -43.06% |
| Earnings Yield | -11.73% |
| FCF Yield | -9.38% |
Analyst Forecast
The average price target for ORIC is $21.43, which is 89.48% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $21.43 |
| Price Target Difference | 89.48% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 16 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |